Pharmacokinetics of etodolac in the horse following oral and intravenous administration
- PMID: 17217400
- DOI: 10.1111/j.1365-2885.2007.00811.x
Pharmacokinetics of etodolac in the horse following oral and intravenous administration
Abstract
The purpose of this study was to determine the pharmacokinetics of etodolac following oral and intravenous administration to six horses. Additionally, in vitro cyclooxygenase (COX) selectivity assays were performed using equine whole blood. Using a randomized two-way crossover design, horses were administered etodolac (20 mg/kg) orally or intravenously, with a minimum 3-week washout period. Plasma samples were collected after administration for analysis using high pressure liquid chromatography with ultraviolet detection. Following intravenous administration, etodolac had a mean plasma half-life (t(1/2)) of 2.67 h, volume of distribution (Vd) of 0.29 L/kg and clearance (Cl) of 234.87 mL/h kg. Following oral administration, the average maximum plasma concentration (Cmax)) was 32.57 mug/mL with a t(1/2) of 3.02 h. Bioavailability was approximately 77.02%. Results of in vitro COX selectivity assays showed that etodolac was only slightly selective for COX-2 with a COX-1/COX-2 selectivity ratio effective concentration (EC)50 of 4.32 and for EC80 of 4.77. This study showed that etodolac is well absorbed in the horse after oral administration, and may offer a useful alternative for anti-inflammatory treatment of various conditions in the horse.
Similar articles
-
The pharmacokinetics and in vitro cyclooxygenase selectivity of deracoxib in horses.J Vet Pharmacol Ther. 2011 Feb;34(1):12-6. doi: 10.1111/j.1365-2885.2010.01185.x. J Vet Pharmacol Ther. 2011. PMID: 21219338 Clinical Trial.
-
Pharmacokinetics and tissue fluid distribution of cephalexin in the horse after oral and i.v. administration.J Vet Pharmacol Ther. 2005 Oct;28(5):425-31. doi: 10.1111/j.1365-2885.2005.00683.x. J Vet Pharmacol Ther. 2005. PMID: 16207304
-
The pharmacokinetics of orbifloxacin in the horse following oral and intravenous administration.J Vet Pharmacol Ther. 2006 Jun;29(3):191-7. doi: 10.1111/j.1365-2885.2006.00737.x. J Vet Pharmacol Ther. 2006. PMID: 16669863 Clinical Trial.
-
1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.Dan Med Bull. 2008 Nov;55(4):186-210. Dan Med Bull. 2008. PMID: 19232159 Review.
-
Pharmacokinetics of sustained-release etodolac.Rheumatol Int. 1993;13(2 Suppl):S3-5. doi: 10.1007/BF00290277. Rheumatol Int. 1993. PMID: 8210922 Review.
Cited by
-
The Clinical Pharmacology and Therapeutic Evaluation of Non-Steroidal Anti-Inflammatory Drugs in Adult Horses.Animals (Basel). 2023 May 10;13(10):1597. doi: 10.3390/ani13101597. Animals (Basel). 2023. PMID: 37238029 Free PMC article. Review.
-
Update on the use of cyclooxygenase-2-selective nonsteroidal anti-inflammatory drugs in horses.J Am Vet Med Assoc. 2017 Jun 1;250(11):1271-1274. doi: 10.2460/javma.250.11.1271. J Am Vet Med Assoc. 2017. PMID: 28509650 Free PMC article. Review.
-
Alterations in the glutathione metabolism could be implicated in the ischemia-induced small intestinal cell damage in horses.BMC Vet Res. 2009 Mar 18;5:10. doi: 10.1186/1746-6148-5-10. BMC Vet Res. 2009. PMID: 19296836 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials